Automating Early Stage Cell Based Assay Development
26 Jul 2017
INTEGRA has published a video demonstrating how US-based biotech contract research specialists Likarda LLC are using VIAFLO ASSIST to cost effectively develop high throughput cell based assays for their customers.
Early phase drug discovery research requires the highest level of accurate and reproducible testing in order to provide the proof to move confidently forward. While Likarda developed and uses a proprietary approach to 3D cell-based testing, the results of these types of tests and others rely on the integrity of the data. In an environment where 'time is money' Likarda clients require quick and accurate results. By investing in robots such as the INTEGRA VIAFLO ASSIST, Likarda has managed to bring speed, accuracy, precision and flexibility to its research and drug discovery.
After careful review of different automation solutions Likarda chose the INTEGRA VIAFLO ASSIST to run a single plate at a time for preliminary experiments, early assay development or pilot studies. The VIAFLO ASSIST removes the risk of less reproducible results compared to manual pipetting, and its electronic pipettes increase the reproducibility of prolonged pipetting protocols such as serial dilutions, plate filling and reagent addition. The intuitive touchscreen control software and ergonomic one-handed operation of the affordably-priced VIAFLO ASSIST has also enabled Likarda to save time developing high throughput assays and lower the cost of this contract work for its customers.